We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Metastatic and synchronous ovarian involvement in low-risk endometrial cancer; clinicopathological analysis with detection of DNA mismatch repair deficiency.
- Authors
Gezer, Şener; Bayrak, Büşra Yaprak
- Abstract
Objectives: This study aimed to investigate ovarian involvement in low-risk endometrial cancer, the associated risk factors, and impact on overall survival. We attempted to explore the differences in mismatch repair (MMR) deficiency between metastatic and synchronous ovarian tumoral involvement. Material and methods: This was a retrospective study of patients with low-risk endometrial cancer who were treated at a tertiary center between January 2006 and December 2019. The primary outcome measures were the incidence and risk factors associated with metastatic and synchronous tumoral involvement of the ovary. Overall, survival data were also analyzed. Metastatic and synchronous tumors were compared with each other in terms of MMR deficiency with IHC staining. Results: From a total of 360 low-risk endometrial cancer patients, 10 (2.8%) had ovarian metastasis and 12 (3.3%) had synchronous ovarian involvement. The median age of patients with metastasis was significantly lower than that of patients without ovarian involvement (49 vs 57 years, p = 0.004). Most patients in the metastatic group were in the < 50 age group (p < 0.001) and premenopausal period (p = 0.001). As a result of IHC staining performed on patients with ovarian involvement, MMR deficiency was found in six (60%) patients in the metastatic group and six (50%) patients in the synchronous group. No significant difference was found in overall survival between groups. Conclusions: Younger age and premenopausal status were risk factors associated with ovarian metastasis. Overall survival did not show differences between all groups, and MMR deficiency was similar between metastatic and synchronous groups.
- Subjects
ENDOMETRIAL cancer risk factors; DNA mismatch repair; OVERALL survival; BODY mass index; ADJUVANT treatment of cancer; NEOADJUVANT chemotherapy
- Publication
Ginekologia Polska, 2021, Vol 92, Issue 9, p599
- ISSN
0017-0011
- Publication type
Article
- DOI
10.5603/GP.a2021.0150